Korean Journal of Radiology

  • 제16권5호
  • /
  • Pages.955-966
  • /
  • 2015
  • /
  • 1229-6929(pISSN)
  • /
  • 2005-8330(eISSN)
대한영상의학회 (The Korean Society of Radiology)
권호 표지
DOI QR코드

DOI QR Code

Nuclear Molecular Imaging for Vulnerable Atherosclerotic Plaques

  • Lee, Soo Jin (Department of Nuclear Medicine, Seoul National University Hospital) ;
  • Paeng, Jin Chul (Department of Nuclear Medicine, Seoul National University Hospital)
  • 투고 : 2015.04.30
  • 심사 : 2015.06.12
  • 발행 : 2015.09.01
⟨ 이전 논문 다음 논문 ⟩

초록

Atherosclerosis is an inflammatory disease as well as a lipid disorder. Atherosclerotic plaque formed in vessel walls may cause ischemia, and the rupture of vulnerable plaque may result in fatal events, like myocardial infarction or stroke. Because morphological imaging has limitations in diagnosing vulnerable plaque, molecular imaging has been developed, in particular, the use of nuclear imaging probes. Molecular imaging targets various aspects of vulnerable plaque, such as inflammatory cell accumulation, endothelial activation, proteolysis, neoangiogenesis, hypoxia, apoptosis, and calcification. Many preclinical and clinical studies have been conducted with various imaging probes and some of them have exhibited promising results. Despite some limitations in imaging technology, molecular imaging is expected to be used both in the research and clinical fields as imaging instruments become more advanced.

키워드

참고문헌

  1. KOSTAT. Causes of death statistics in Korean. http://kostat.go.kr/portal/korea/kor_nw/2/1/index.board?bmode=read&aSeq=330181. Published September 23, 2014. Accessed April 23, 2015
  2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation 2015;131:e29-e322 https://doi.org/10.1161/CIR.0000000000000152
  3. Tuzcu EM, Kapadia SR, Tutar E, Ziada KM, Hobbs RE, McCarthy PM, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 2001;103:2705-2710 https://doi.org/10.1161/01.CIR.103.22.2705
  4. Hackett D, Davies G, Maseri A. Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. Eur Heart J 1988;9:1317-1323 https://doi.org/10.1093/oxfordjournals.eurheartj.a062449
  5. Murabito JM, Evans JC, Larson MG, Levy D. Prognosis after the onset of coronary heart disease. An investigation of differences in outcome between the sexes according to initial coronary disease presentation. Circulation 1993;88:2548-2555 https://doi.org/10.1161/01.CIR.88.6.2548
  6. Skålen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002;417:750-754 https://doi.org/10.1038/nature00804
  7. Kruth HS. Sequestration of aggregated low-density lipoproteins by macrophages. Curr Opin Lipidol 2002;13:483-488 https://doi.org/10.1097/00041433-200210000-00003
  8. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell 2001;104:503-516 https://doi.org/10.1016/S0092-8674(01)00238-0
  9. Miller YI, Chang MK, Binder CJ, Shaw PX, Witztum JL. Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol 2003;14:437-445 https://doi.org/10.1097/00041433-200310000-00004
  10. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001;107:1255-1262 https://doi.org/10.1172/JCI11871
  11. Amorino GP, Hoover RL. Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production. Am J Pathol 1998;152:199-207
  12. Mason DP, Kenagy RD, Hasenstab D, Bowen-Pope DF, Seifert RA, Coats S, et al. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. Circ Res 1999;85:1179-1185 https://doi.org/10.1161/01.RES.85.12.1179
  13. Sukhova GK, Schönbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999;99:2503-2509 https://doi.org/10.1161/01.CIR.99.19.2503
  14. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999;99:1726-1732 https://doi.org/10.1161/01.CIR.99.13.1726
  15. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005;25:2054-2061 https://doi.org/10.1161/01.ATV.0000178991.71605.18
  16. Iuliano L, Signore A, Vallabajosula S, Colavita AR, Camastra C, Ronga G, et al. Preparation and biodistribution of 99m technetium labelled oxidized LDL in man. Atherosclerosis 1996;126:131-141 https://doi.org/10.1016/0021-9150(96)05888-1
  17. Tsimikas S, Palinski W, Halpern SE, Yeung DW, Curtiss LK, Witztum JL. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol 1999;6(1 Pt 1):41-53 https://doi.org/10.1016/S1071-3581(99)90064-8
  18. Shaw PX, Hörkkö S, Tsimikas S, Chang MK, Palinski W, Silverman GJ, et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 2001;21:1333-1339 https://doi.org/10.1161/hq0801.093587
  19. Tekabe Y, Li Q, Rosario R, Sedlar M, Majewski S, Hudson BI, et al. Development of receptor for advanced glycation end products-directed imaging of atherosclerotic plaque in a murine model of spontaneous atherosclerosis. Circ Cardiovasc Imaging 2008;1:212-219 https://doi.org/10.1161/CIRCIMAGING.108.788299
  20. Nakamura I, Hasegawa K, Wada Y, Hirase T, Node K, Watanabe Y. Detection of early stage atherosclerotic plaques using PET and CT fusion imaging targeting P-selectin in low density lipoprotein receptor-deficient mice. Biochem Biophys Res Commun 2013;433:47-51 https://doi.org/10.1016/j.bbrc.2013.02.069
  21. Broisat A, Toczek J, Dumas LS, Ahmadi M, Bacot S, Perret P, et al. 99mTc-cAbVCAM1-5 imaging is a sensitive and reproducible tool for the detection of inflamed atherosclerotic lesions in mice. J Nucl Med 2014;55:1678-1684 https://doi.org/10.2967/jnumed.114.143792
  22. Nahrendorf M, Keliher E, Panizzi P, Zhang H, Hembrador S, Figueiredo JL, et al. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovasc Imaging 2009;2:1213-1222 https://doi.org/10.1016/j.jcmg.2009.04.016
  23. Li X, Bauer W, Israel I, Kreissl MC, Weirather J, Richter D, et al. Targeting P-selectin by gallium-68-labeled fucoidan positron emission tomography for noninvasive characterization of vulnerable plaques: correlation with in vivo 17.6T MRI. Arterioscler Thromb Vasc Biol 2014;34:1661-1667 https://doi.org/10.1161/ATVBAHA.114.303485
  24. Kircher MF, Grimm J, Swirski FK, Libby P, Gerszten RE, Allport JR, et al. Noninvasive in vivo imaging of monocyte trafficking to atherosclerotic lesions. Circulation 2008;117:388-395 https://doi.org/10.1161/CIRCULATIONAHA.107.719765
  25. Ogawa M, Ishino S, Mukai T, Asano D, Teramoto N, Watabe H, et al. (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med 2004;45:1245-1250
  26. Aziz K, Berger K, Claycombe K, Huang R, Patel R, Abela GS. Noninvasive detection and localization of vulnerable plaque and arterial thrombosis with computed tomography angiography/positron emission tomography. Circulation 2008;117:2061-2070 https://doi.org/10.1161/CIRCULATIONAHA.106.652313
  27. Davies JR, Izquierdo-Garcia D, Rudd JH, Figg N, Richards HK, Bird JL, et al. FDG-PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis. Int J Cardiovasc Imaging 2010;26:41-48
  28. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002;105:2708-2711 https://doi.org/10.1161/01.CIR.0000020548.60110.76
  29. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006;48:1818-1824 https://doi.org/10.1016/j.jacc.2006.05.076
  30. Graebe M, Pedersen SF, Borgwardt L, Hojgaard L, Sillesen H, Kjaer A. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg 2009;37:714-721 https://doi.org/10.1016/j.ejvs.2008.11.018
  31. Silvera SS, Aidi HE, Rudd JH, Mani V, Yang L, Farkouh M, et al. Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. Atherosclerosis 2009;207:139-143 https://doi.org/10.1016/j.atherosclerosis.2009.04.023
  32. Wu YW, Kao HL, Chen MF, Lee BC, Tseng WY, Jeng JS, et al. Characterization of plaques using 18F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase-1. J Nucl Med 2007;48:227-233
  33. Tahara N, Kai H, Yamagishi S, Mizoguchi M, Nakaura H, Ishibashi M, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol 2007;49:1533-1539 https://doi.org/10.1016/j.jacc.2006.11.046
  34. Lee DH, Lee SJ, Lee DJ, Kwon SH, Jo KS, An YS, et al. Carotid Artery FDG Uptake May Serve as a Biomarker for Cardiovascular Risk Stratification in Asymptomatic Adults. Nucl Med Mol Imaging 2014;48:196-202 https://doi.org/10.1007/s13139-014-0277-1
  35. Wasselius J, Larsson S, Sundin A, Jacobsson H. Assessment of inactive, active and mixed atherosclerotic plaques by 18F-FDG-PET; an age group-based correlation with cardiovascular risk factors. Int J Cardiovasc Imaging 2009;25:133-140 https://doi.org/10.1007/s10554-008-9366-5
  36. Bural GG, Torigian DA, Chamroonrat W, Houseni M, Chen W, Basu S, et al. FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging 2008;35:562-569 https://doi.org/10.1007/s00259-007-0528-9
  37. Ben-Haim S, Kupzov E, Tamir A, Frenkel A, Israel O. Changing patterns of abnormal vascular wall F-18 fluorodeoxyglucose uptake on follow-up PET/CT studies. J Nucl Cardiol 2006;13:791-800 https://doi.org/10.1016/j.nuclcard.2006.07.008
  38. Rudd JH, Myers KS, Bansilal S, Machac J, Woodward M, Fuster V, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging 2009;2:107-115 https://doi.org/10.1161/CIRCIMAGING.108.811752
  39. Wasselius JA, Larsson SA, Jacobsson H. FDG-accumulating atherosclerotic plaques identified with 18F-FDG-PET/CT in 141 patients. Mol Imaging Biol 2009;11:455-459 https://doi.org/10.1007/s11307-009-0223-2
  40. Figueroa AL, Abdelbaky A, Truong QA, Corsini E, MacNabb MH, Lavender ZR, et al. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. JACC Cardiovasc Imaging 2013;6:1250-1259 https://doi.org/10.1016/j.jcmg.2013.08.006
  41. Muller HF, Viaccoz A, Fisch L, Bonvin C, Lovblad KO, Ratib O, et al. 18FDG-PET-CT: an imaging biomarker of high-risk carotid plaques. Correlation to symptoms and microembolic signals. Stroke 2014;45:3561-3566 https://doi.org/10.1161/STROKEAHA.114.006488
  42. Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med 2009;50:1611-1620 https://doi.org/10.2967/jnumed.109.065151
  43. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006;48:1825-1831 https://doi.org/10.1016/j.jacc.2006.03.069
  44. Potter K, Lenzo N, Eikelboom JW, Arnolda LF, Beer C, Hankey GJ. Effect of long-term homocysteine reduction with B vitamins on arterial wall inflammation assessed by fluorodeoxyglucose positron emission tomography: a randomised double-blind, placebo-controlled trial. Cerebrovasc Dis 2009;27:259-265 https://doi.org/10.1159/000199463
  45. Jeong J, Kong E, Chun K, Cho I. The Impact of Energy Substrates, Hormone Level and Subject-Related Factors on Physiologic Myocardial (18)F-FDG Uptake in Normal Humans. Nucl Med Mol Imaging 2013;47:225-231 https://doi.org/10.1007/s13139-013-0230-8
  46. Morooka M, Moroi M, Uno K, Ito K, Wu J, Nakagawa T, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res 2014;4:1 https://doi.org/10.1186/2191-219X-4-1
  47. Gormsen LC, Christensen NL, Bendstrup E, Tolbod LP, Nielsen SS. Complete somatostatin-induced insulin suppression combined with heparin loading does not significantly suppress myocardial 18F-FDG uptake in patients with suspected cardiac sarcoidosis. J Nucl Cardiol 2013;20:1108-1115 https://doi.org/10.1007/s12350-013-9798-8
  48. Harisankar CN, Mittal BR, Agrawal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol 2011;18:926-936 https://doi.org/10.1007/s12350-011-9422-8
  49. Annovazzi A, Bonanno E, Arca M, D’Alessandria C, Marcoccia A, Spagnoli LG, et al. 99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques. Eur J Nucl Med Mol Imaging 2006;33:117-126 https://doi.org/10.1007/s00259-005-1899-4
  50. Elmaleh DR, Narula J, Babich JW, Petrov A, Fischman AJ, Khaw BA, et al. Rapid noninvasive detection of experimental atherosclerotic lesions with novel 99mTc-labeled diadenosine tetraphosphates. Proc Natl Acad Sci U S A 1998;95:691-695 https://doi.org/10.1073/pnas.95.2.691
  51. Tepe G, Duda SH, Meding J, Brehme U, Ritter J, Hanke H, et al. Tc-99m-labeled endothelin derivative for imaging of experimentally induced atherosclerosis. Atherosclerosis 2001;157:383-392 https://doi.org/10.1016/S0021-9150(00)00753-X
  52. Glaudemans AW, Bonanno E, Galli F, Zeebregts CJ, de Vries EF, Koole M, et al. In vivo and in vitro evidence that 99mTc-HYNIC-interleukin-2 is able to detect T lymphocytes in vulnerable atherosclerotic plaques of the carotid artery. Eur J Nucl Med Mol Imaging 2014;41:1710-1719 https://doi.org/10.1007/s00259-014-2764-0
  53. Liu Y, Pierce R, Luehmann HP, Sharp TL, Welch MJ. PET imaging of chemokine receptors in vascular injury-accelerated atherosclerosis. J Nucl Med 2013;54:1135-1141 https://doi.org/10.2967/jnumed.112.114777
  54. Luehmann HP, Pressly ED, Detering L, Wang C, Pierce R, Woodard PK, et al. PET/CT imaging of chemokine receptor CCR5 in vascular injury model using targeted nanoparticle. J Nucl Med 2014;55:629-634 https://doi.org/10.2967/jnumed.113.132001
  55. Winkel LC, Groen HC, van Thiel BS, Muller C, van der Steen AF, Wentzel JJ, et al. Folate receptor-targeted single-photon emission computed tomography/computed tomography to detect activated macrophages in atherosclerosis: can it distinguish vulnerable from stable atherosclerotic plaques? Mol Imaging 2014;13
  56. Jager NA, Westra J, Golestani R, van Dam GM, Low PS, Tio RA, et al. Folate receptor-${\beta}$ imaging using 99mTc-folate to explore distribution of polarized macrophage populations in human atherosclerotic plaque. J Nucl Med 2014;55:1945-1951 https://doi.org/10.2967/jnumed.114.143180
  57. Tahara N, Mukherjee J, de Haas HJ, Petrov AD, Tawakol A, Haider N, et al. 2-deoxy-2-[18F]fluoro-D-mannose positron emission tomography imaging in atherosclerosis. Nat Med 2014;20:215-219 https://doi.org/10.1038/nm.3437
  58. Li D, Patel AR, Klibanov AL, Kramer CM, Ruiz M, Kang BY, et al. Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance. Circ Cardiovasc Imaging 2010;3:464-472 https://doi.org/10.1161/CIRCIMAGING.109.896654
  59. Rominger A, Saam T, Vogl E, Ubleis C, la Fougère C, Förster S, et al. In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors. J Nucl Med 2010;51:193-197 https://doi.org/10.2967/jnumed.109.070672
  60. Li X, Samnick S, Lapa C, Israel I, Buck AK, Kreissl MC, et al. 68Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with18F-FDG, calcium burden and risk factors. EJNMMI Res 2012;2:52 https://doi.org/10.1186/2191-219X-2-52
  61. Mojtahedi A, Alavi A, Thamake S, Amerinia R, Ranganathan D, Tworowska I, et al. Assessment of vulnerable atherosclerotic and fibrotic plaques in coronary arteries using (68)Ga-DOTATATE PET/CT. Am J Nucl Med Mol Imaging 2014;5:65-71
  62. Laitinen I, Marjamäki P, Någren K, Laine VJ, Wilson I, Leppänen P, et al. Uptake of inflammatory cell marker [11C]PK11195 into mouse atherosclerotic plaques. Eur J Nucl Med Mol Imaging 2009;36:73-80 https://doi.org/10.1007/s00259-008-0919-6
  63. Bird JL, Izquierdo-Garcia D, Davies JR, Rudd JH, Probst KC, Figg N, et al. Evaluation of translocator protein quantification as a tool for characterising macrophage burden in human carotid atherosclerosis. Atherosclerosis 2010;210:388-391 https://doi.org/10.1016/j.atherosclerosis.2009.11.047
  64. Pugliese F, Gaemperli O, Kinderlerer AR, Lamare F, Shalhoub J, Davies AH, et al. Imaging of vascular inflammation with [11C]-PK11195 and positron emission tomography/computed tomography angiography. J Am Coll Cardiol 2010;56:653-661 https://doi.org/10.1016/j.jacc.2010.02.063
  65. Gaemperli O, Shalhoub J, Owen DR, Lamare F, Johansson S, Fouladi N, et al. Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. Eur Heart J 2012;33:1902-1910 https://doi.org/10.1093/eurheartj/ehr367
  66. Laitinen IE, Luoto P, Någren K, Marjamäki PM, Silvola JM, Hellberg S, et al. Uptake of 11C-choline in mouse atherosclerotic plaques. J Nucl Med 2010;51:798-802 https://doi.org/10.2967/jnumed.109.071704
  67. Bucerius J, Schmaljohann J, Böhm I, Palmedo H, Guhlke S, Tiemann K, et al. Feasibility of 18F-fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans--first results. Eur J Nucl Med Mol Imaging 2008;35:815-820 https://doi.org/10.1007/s00259-007-0685-x
  68. Kato K, Schober O, Ikeda M, Schäfers M, Ishigaki T, Kies P, et al. Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT. Eur J Nucl Med Mol Imaging 2009;36:1622-1628 https://doi.org/10.1007/s00259-009-1152-7
  69. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008;117:379-387 https://doi.org/10.1161/CIRCULATIONAHA.107.741181
  70. Schafers M, Riemann B, Kopka K, Breyholz HJ, Wagner S, Schafers KP, et al. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation 2004;109:2554-2559 https://doi.org/10.1161/01.CIR.0000129088.49276.83
  71. Fujimoto S, Hartung D, Ohshima S, Edwards DS, Zhou J, Yalamanchili P, et al. Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: resolution with dietary modification and statin therapy. J Am Coll Cardiol 2008;52:1847-1857 https://doi.org/10.1016/j.jacc.2008.08.048
  72. Breyholz HJ, Wagner S, Levkau B, Schober O, Schäfers M, Kopka K. A 18F-radiolabeled analogue of CGS 27023A as a potential agent for assessment of matrix-metalloproteinase activity in vivo. Q J Nucl Med Mol Imaging 2007;51:24-32
  73. Tavakoli S, Razavian M, Zhang J, Nie L, Marfatia R, Dobrucki LW, et al. Matrix metalloproteinase activation predicts amelioration of remodeling after dietary modification in injured arteries. Arterioscler Thromb Vasc Biol 2011;31:102-109 https://doi.org/10.1161/ATVBAHA.110.216036
  74. Razavian M, Tavakoli S, Zhang J, Nie L, Dobrucki LW, Sinusas AJ, et al. Atherosclerosis plaque heterogeneity and response to therapy detected by in vivo molecular imaging of matrix metalloproteinase activation. J Nucl Med 2011;52:1795-1802 https://doi.org/10.2967/jnumed.111.092379
  75. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17:1359-1370 https://doi.org/10.1038/nm.2537
  76. Razavian M, Marfatia R, Mongue-Din H, Tavakoli S, Sinusas AJ, Zhang J, et al. Integrin-targeted imaging of inflammation in vascular remodeling. Arterioscler Thromb Vasc Biol 2011;31:2820-2826 https://doi.org/10.1161/ATVBAHA.111.231654
  77. Paeng JC, Lee YS, Lee JS, Jeong JM, Kim KB, Chung JK, et al. Feasibility and kinetic characteristics of (68)Ga-NOTA-RGD PET for in vivo atherosclerosis imaging. Ann Nucl Med 2013;27:847-854 https://doi.org/10.1007/s12149-013-0757-x
  78. Su H, Gorodny N, Gomez LF, Gangadharmath UB, Mu F, Chen G, et al. Atherosclerotic plaque uptake of a novel integrin tracer 18F-Flotegatide in a mouse model of atherosclerosis. J Nucl Cardiol 2014;21:553-562 https://doi.org/10.1007/s12350-014-9879-3
  79. Beer AJ, Pelisek J, Heider P, Saraste A, Reeps C, Metz S, et al. PET/CT imaging of integrin ${\alpha}v{\beta}3$ expression in human carotid atherosclerosis. JACC Cardiovasc Imaging 2014;7:178-187 https://doi.org/10.1016/j.jcmg.2013.12.003
  80. Laitinen I, Saraste A, Weidl E, Poethko T, Weber AW, Nekolla SG, et al. Evaluation of alphavbeta3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice. Circ Cardiovasc Imaging 2009;2:331-338 https://doi.org/10.1161/CIRCIMAGING.108.846865
  81. Kim YI, Phi JH, Paeng JC, Choi H, Kim SK, Lee YS, et al. In vivo evaluation of angiogenic activity and its correlation with efficacy of indirect revascularization surgery in pediatric moyamoya disease. J Nucl Med 2014;55:1467-1472 https://doi.org/10.2967/jnumed.114.142430
  82. Golestani R, Zeebregts CJ, Terwisscha van Scheltinga AG, Lub-de Hooge MN, van Dam GM, Glaudemans AW, et al. Feasibility of vascular endothelial growth factor imaging in human atherosclerotic plaque using (89)Zr-bevacizumab positron emission tomography. Mol Imaging 2013;12:235-243
  83. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008;49 Suppl 2:129S-148S https://doi.org/10.2967/jnumed.107.045914
  84. Mateo J, Izquierdo-Garcia D, Badimon JJ, Fayad ZA, Fuster V. Noninvasive assessment of hypoxia in rabbit advanced atherosclerosis using 18F-fluoromisonidazole positron emission tomographic imaging. Circ Cardiovasc Imaging 2014;7:312-320 https://doi.org/10.1161/CIRCIMAGING.113.001084
  85. Kolodgie FD, Petrov A, Virmani R, Narula N, Verjans JW, Weber DK, et al. Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: a technique with potential for noninvasive imaging of vulnerable plaque. Circulation 2003;108:3134-3139 https://doi.org/10.1161/01.CIR.0000105761.00573.50
  86. Johnson LL, Schofield L, Donahay T, Narula N, Narula J. 99mTc-annexin V imaging for in vivo detection of atherosclerotic lesions in porcine coronary arteries. J Nucl Med 2005;46:1186-1193
  87. Isobe S, Tsimikas S, Zhou J, Fujimoto S, Sarai M, Branks MJ, et al. Noninvasive imaging of atherosclerotic lesions in apolipoprotein E-deficient and low-density-lipoprotein receptor-deficient mice with annexin A5. J Nucl Med 2006;47:1497-1505
  88. Dweck MR, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM, et al. Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol 2012;59:1539-1548 https://doi.org/10.1016/j.jacc.2011.12.037
  89. Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet 2014;383:705-713 https://doi.org/10.1016/S0140-6736(13)61754-7
  90. Derlin T, Richter U, Bannas P, Begemann P, Buchert R, Mester J, et al. Feasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaque. J Nucl Med 2010;51:862-865 https://doi.org/10.2967/jnumed.110.076471
  91. Derlin T, Tóth Z, Papp L, Wisotzki C, Apostolova I, Habermann CR, et al. Correlation of inflammation assessed by 18F-FDG PET, active mineral deposition assessed by 18F-fluoride PET, and vascular calcification in atherosclerotic plaque: a dual-tracer PET/CT study. J Nucl Med 2011;52:1020-1027 https://doi.org/10.2967/jnumed.111.087452
  92. Derlin T, Wisotzki C, Richter U, Apostolova I, Bannas P, Weber C, et al. In vivo imaging of mineral deposition in carotid plaque using 18F-sodium fluoride PET/CT: correlation with atherogenic risk factors. J Nucl Med 2011;52:362-368 https://doi.org/10.2967/jnumed.110.081208
  93. Li Y, Berenji GR, Shaba WF, Tafti B, Yevdayev E, Dadparvar S. Association of vascular fluoride uptake with vascular calcification and coronary artery disease. Nucl Med Commun 2012;33:14-20 https://doi.org/10.1097/MNM.0b013e32834c187e
  94. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol 2007;50:892-896 https://doi.org/10.1016/j.jacc.2007.05.024
  95. Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med 2008;49:871-878 https://doi.org/10.2967/jnumed.107.050294
  96. Wasselius J, Larsson S, Jacobsson H. Time-to-time correlation of high-risk atherosclerotic lesions identified with [(18)F]-FDG-PET/CT. Ann Nucl Med 2009;23:59-64 https://doi.org/10.1007/s12149-008-0207-3

피인용 문헌

  1. SPECT and PET imaging of angiogenesis and arteriogenesis in pre-clinical models of myocardial ischemia and peripheral vascular disease vol.43, pp.13, 2015, https://doi.org/10.1007/s00259-016-3480-8
  2. Incremental value of PET and MRI in the evaluation of cardiovascular abnormalities vol.7, pp.4, 2015, https://doi.org/10.1007/s13244-016-0494-5
  3. Noninvasive detection of matrix metalloproteinase-9 in atherosclerotic lesions using technetium-99m-labeled single-photon emission computed tomography in vivo vol.38, pp.4, 2015, https://doi.org/10.1097/mnm.0000000000000651
  4. Nanoparticles for Detection and Treatment of Peripheral Arterial Disease vol.14, pp.32, 2018, https://doi.org/10.1002/smll.201800644
  5. Measurement of 68Ga-DOTATOC Uptake in the Thoracic Aorta and Its Correlation with Cardiovascular Risk vol.52, pp.4, 2015, https://doi.org/10.1007/s13139-018-0524-y
  6. Molecular Imaging of Vulnerable Coronary Plaque with Radiolabeled Somatostatin Receptors (SSTR) vol.10, pp.23, 2015, https://doi.org/10.3390/jcm10235515